Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 120,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 120,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Trading Down 2.4 %

Shares of NASDAQ:TEM traded down $0.99 during midday trading on Friday, reaching $41.00. 5,041,241 shares of the company were exchanged, compared to its average volume of 1,427,998. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The stock’s fifty day moving average price is $52.88. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Sandia Investment Management LP acquired a new position in Tempus AI during the second quarter worth $136,000. Vestor Capital LLC bought a new position in Tempus AI in the third quarter valued at $153,000. Stifel Financial Corp acquired a new stake in Tempus AI in the 3rd quarter valued at $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI during the 3rd quarter worth about $258,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of recent analyst reports. Loop Capital upped their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Bank of America upped their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.